Bronchial Trans-epithelial Transport in Patients With Idiopathic Multiple Dilations of the Bronchi

NCT ID: NCT02586883

Last Updated: 2021-04-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

42 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-03-29

Study Completion Date

2020-11-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to identify the abnormalities of bronchial trans-epithelial transport of chloride, sodium and bicarbonate in patients with idiopathic dilations of the bronchi.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Dilations of the bronchi happens for one child over 3000. The extended forms may progress to respiratory failure. More than one case over two remains of undetermined cause. If the prototype is the cystic fibrosis, other abnormalities of ionic transport may be the cause of a failure of mucociliary clearance and enhance the idiopathic dilations of the bronchi.

The purpose of this study is to identify the abnormalities of bronchial trans-epithelial transport of chloride, sodium and bicarbonate in patients with idiopathic dilations of the bronchi, in comparison to two others groups of patients (without abnormality of ionic transport/with typical cystic fibrosis).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Idiopathic Dilation of the Bronchi

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with multiple bronchi dilations

Group Type EXPERIMENTAL

bronchial ddp test

Intervention Type OTHER

bronchial ddp test during endoscopy, nasal smear, bronchial smear

Control patients without transport abnormality

Group Type ACTIVE_COMPARATOR

bronchial ddp test

Intervention Type OTHER

bronchial ddp test during endoscopy, nasal smear, bronchial smear

Patients with typical cystic fibrosis

Group Type ACTIVE_COMPARATOR

bronchial ddp test

Intervention Type OTHER

bronchial ddp test during endoscopy, nasal smear, bronchial smear

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

bronchial ddp test

bronchial ddp test during endoscopy, nasal smear, bronchial smear

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Common criteria for all patients

* Age between 2 and 20 years.
* Patient weighing more than 12kg
* Patients with a scheduled bronchoscopy under clinical monitoring (assessment of bronchial involvement, local samples for bacteriological and histological examination)
* Signature of consent by the patient or by the / the holder (s) of parental authority and the investigator
* Patient affiliated to a social security scheme or entitled
* Patient with contraception (for woman of childbearing age) Specific criteria for idiopathic bronchiectasis patients Patient with idiopathic bronchiectasis in at least two lobes, diagnosis made after extensive screening of known acquired or congenital causes

Specific criteria for "control" patients without abnormal ion transport

* Patient Not having bronchiectasis s or any supposed alteration in transepithelial ion transport
* Patients with fiberoptic bronchoscopy performed for one of the following indications:
* Pulmonary malformations
* Laryngeal, tracheal, bronchomalacia
* Airway compression
* Interstitial pathology
* Suspicion of foreign body
* Suspected tuberculosis Specific criteria for patients with a typical form of cystic f ibrosis (CF) Patient carrying 2 causing mutations in the CFTR gene (according to CFTR2 database; http://www.cftr2.org/mutations\_history.php) and sweat test\> 60 milliequivalent per liter (mEq/L).

Exclusion Criteria

Common criteria for all patients

* Smoking passive or active
* Not essential bronchial endoscopy in the clinical follow
* Extension of bronchoscopy time attributed to the difference in potential bronchial incompatible with the patient's general status
* Patient pregnant or breast feeding
* Hypersensitivity or cons known contraindications to health products for measurement of DDP (isoproterenol, Amiloride, ATP)

Specific criteria for idiopathic DDB patients

Presence of other congenital or acquired etiologies of DDB:

* Typical or atypical cystic fibrosis,
* Immunodeficiency,
* Primary ciliary dyskinesia,
* Abnormal bronchial wall structure (Williams-Campbell syndrome, Mounier-Kuhn, Ehlers-Danlos syndrome, Marfan's disease)
* Infectious DDBs post
* Extrinsic or endobronchial obstruction (foreign body, malformation, middle lobe syndrome)
* Chronic inhalation (GERD, swallowing disorders, gastroesophageal tracheal fistula)
* Allergic bronchopulmonary aspergillosis,
* System disease.
Minimum Eligible Age

2 Years

Maximum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Necker-Enfants Malades Hospital

Paris, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2015-A00731-48

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Bronchial Asthma & Its Exacerbation
NCT06331897 NOT_YET_RECRUITING
Interstitial Lung Disease Exacerbations Study
NCT06685874 ACTIVE_NOT_RECRUITING